ABSTRACT
Appropriate management can greatly reduce the fetal and maternal morbidity in antiphospholipid syndrome (APS), an autoimmune disease that is now recognized as a leading cause of recurrent pregnancy loss (RPL). RPL occurs in about 1% of women.1,2
In about 15% of otherwise-healthy women, antiphospholipid antibodies (aPL) appear to be the sole explanation for their pregnancy loss.3,4 aPL have also been associated with:
● preterm birth, prior to 34 weeks’ gestation5,6
● placental insufficiency and fetal growth restriction5,6
● preeclampsia5,6
● venous, arterial, and small-vessel thrombophilia7,8
The aims of therapy of APS during pregnancy include the improvement of all these morbidities.
